The company is building a pipeline of innovative drugs to improve the lives of patients by preventing the cognitive and functional decline associated with neurodegeneration. Their small molecule-based drug discovery platform specializes in the development of oral inhibitors of amyloid neurotoxicity by inhibiting protein misfolding and aggregation based on individual genetic and biological information, thereby helping the healthcare industry to treat neurological disorders in an efficient manner.